Entera Bio Announces That Post-Hoc Data From Its Phase 2 Clinical Trial Of EB613Has Been Selected For Two Presentations At The American Society For Bone And Mineral Research Annual Meeting

Loading news article.

Entera Bio Announces That Post-Hoc Data From Its Phase 2 Clinical Trial Of EB613Has Been Selected For Two Presentations At The American Society For Bone And Mineral Research Annual Meeting | WAPE

Entera Bio Announces That Post-Hoc Data From Its Phase 2 Clinical Trial Of EB613Has Been Selected For Two Presentations At The American Society For Bone And Mineral Research Annual Meeting

Article summary

Related companies

Comments —